2013
DOI: 10.1002/ardp.201300231
|View full text |Cite
|
Sign up to set email alerts
|

Oxadiazoles as Privileged Motifs for Promising Anticancer Leads: Recent Advances and Future Prospects

Abstract: Taking into account the rising trend of the incidence of cancers of various organs, effective therapies are urgently needed to control human malignancies. The rapid emergence of hundreds of new agents that modulate an ever-growing list of cancer-specific molecular targets offers tremendous hope for cancer patients. However, almost all of the chemotherapy drugs currently on the market cause serious side effects. Based on these facts, the design of new chemical entities as anticancer agents requires the simulati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
20
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 59 publications
(20 citation statements)
references
References 126 publications
(119 reference statements)
0
20
0
Order By: Relevance
“…Additionally, 1,3,4-oxadiazole has emerged as an important scaffold owing to its metabolic profile and ability to engage in hydrogen bonding with receptor site. Recent studies have indicated that 1,3,4-oxadiazole derivatives exhibit potent anticancer activity against different cancer cell lines through the inhibition of different growth factors, enzymes and kinases including telomerase, histone deacetylase (HDAC), methionine aminopeptidase (MetAP), thymidylate synthase (TS), glycogen synthase kinase-3 (GSK), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and focal adhesion kinase (FAK) [24][25][26]. Triazoles [27], tetrazoles [28], thiadiazoles [29], and pyrimidines [4] have also been reported to show anticancer activity.…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, 1,3,4-oxadiazole has emerged as an important scaffold owing to its metabolic profile and ability to engage in hydrogen bonding with receptor site. Recent studies have indicated that 1,3,4-oxadiazole derivatives exhibit potent anticancer activity against different cancer cell lines through the inhibition of different growth factors, enzymes and kinases including telomerase, histone deacetylase (HDAC), methionine aminopeptidase (MetAP), thymidylate synthase (TS), glycogen synthase kinase-3 (GSK), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and focal adhesion kinase (FAK) [24][25][26]. Triazoles [27], tetrazoles [28], thiadiazoles [29], and pyrimidines [4] have also been reported to show anticancer activity.…”
Section: Introductionmentioning
confidence: 99%
“…Chemically, most current synthetic anticancer drugs are heterocyclic compounds and nitrogen heterocycles [9][10][11][12]. This fact is observed by analyzing the chemical structures of some anticancer drugs approved by the FDA (Food and drug administration) in 2017, which share a pyrimidine scaffold as part of their structures (Figure 1).…”
Section: Introductionmentioning
confidence: 99%
“…A wide range of biologically active pharmacophores possess these five-membered heteroaromatic ring systems with remarkable biological properties including sphinosine kinase inhibitor [ 29 ], diacylglycerol acyltransferase 1 (DGAT-1) inhibitor [ 30 ], glycogen synthase kinase (GSK-3) inhibitor [ 31 ], sirtuin (SIRT) inhibitor [ 32 ] and methionine aminopeptidase inhibitor activities [ 33 ]. Some diterpenic 1,2,4- and 1,3,4-oxadiazoles, including steroid-based compounds, have also shown remarkable antiproliferative action on adherent human cancer cell lines [ 25 , 26 , 34 , 35 , 36 , 37 ].…”
Section: Introductionmentioning
confidence: 99%